Oncology Peer Review On-The-Go: 1-on-1 with Zuri Murrell, MD: Colorectal Cancer in Black Patients

Podcast

The latest episode of CancerNetwork’s podcast focuses on the rising incidence rates of colorectal cancer in both young and black patients.

In this edition “Oncology Peer Review On-The-Go,” CancerNetwork spoke with Zuri Murrell, MD, 1-on-1 for a conversation regarding the rising rates of colorectal cancer for younger individuals, as well as the significantly higher incidence and death rates for Black patients of this cancer type.

According to the American Cancer Society, colorectal cancer is the second-leading cause of cancer deaths in the US in men and women combined. Murrell, a colorectal surgeon and cancer specialist at Cedars-Sinai, explained that obesity, diabetes, smoking, and a family history of colorectal cancer may all play a role in the increasing rate.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Related Content